CA2376159A1 - Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method - Google Patents

Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method Download PDF

Info

Publication number
CA2376159A1
CA2376159A1 CA002376159A CA2376159A CA2376159A1 CA 2376159 A1 CA2376159 A1 CA 2376159A1 CA 002376159 A CA002376159 A CA 002376159A CA 2376159 A CA2376159 A CA 2376159A CA 2376159 A1 CA2376159 A1 CA 2376159A1
Authority
CA
Canada
Prior art keywords
drug
derivatives
pharmaceutical preparation
binding affinity
plasma protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002376159A
Other languages
French (fr)
Other versions
CA2376159C (en
Inventor
Keiichi Kawai
Norito Takamura
Ryuichi Nishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376159A1 publication Critical patent/CA2376159A1/en
Application granted granted Critical
Publication of CA2376159C publication Critical patent/CA2376159C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3

Abstract

A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method is characterized in that, in the administration of a first drug having binding affinity for plasma protein, a second drug having binding affinity for the same plasma protein is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.

Claims (13)

1. (Amended) A pharmaceutical preparation with binding affinity for plasma protein which comprises a single or plural second drug, characterized in that the second drug has binding affinity for the same plasma protein for which a first drug has binding affinity and the pharmaceutical preparation is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.
2. (Amended) The pharmaceutical preparation according to Claim 1, wherein the second drug has binding affinity to the same binding sites on the plasma protein to which the first drug has binding affinity.
3. (Amended) The pharmaceutical preparation according to Claim 1 or 2, wherein the first drug is a radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use.
4. (Amended) The pharmaceutical preparation according to Claim 3, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (11C), 15-oxygen (15O), 18-fluorine, (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201T1), 212-bismuth (212Bi), 213-bismuth (213Bi) and 211-astatine (211At).
5. (Amended) The pharmaceutical preparation according to Claim 3, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamidobisthiol or its derivatives, mercaptoacetyl-glycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives, methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivative, .beta.-methyl-.omega.-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid and benzylguanidine and tropane derivatives.
6. (Amended) The pharmaceutical preparation according to any one of claims 1 to 3, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.
7. A pharmaceutical preparation characterized by regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for plasma protein and a single or plural second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.
8. The pharmaceutical preparation according to Claim 7, wherein each of the first drug and the second drug is separately filled in a container, and prepared as kit form for supply.
9. The pharmaceutical preparation according to Claim 7 or 8, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.
10. The pharmaceutical preparation according to any one of Claims 7 to 9, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.
11. The pharmaceutical preparation according to Claim 10, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (11C), 15-oxygen (15O), 18-fluorine (18F), 32-phosphorus (32P), 59-iron (59Fe), 67-copper (67Cu), 67-gallium (67Ga), 81m-krypton (81m Kr), 81-rubidium (81Rb), 89-strontium (89Sr), 90-yttrium (90Y), 99m-technetium (99m Tc), 111-indium (111In), 123-iodine (123I), 125-iodine (125I), 131-iodine (131I), 133-xenon (133Xe), 117m-tin (117m Sn), 153-samarium (153Sm), 186-rhenium (186Re), 188-rhenium (188Re), 201-thallium (201Tl), 212-bismuth (212Bi), 213-bismuth (213Bi) and 211-astatine (211At).
12. The pharmaceutical preparation according to Claim 10, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of bisaminothiol or its derivatives, monoaminomonoamidobisthiol or its derivatives, bisamidobisthiol or its derivatives, mercapto-acetylglycylglycylglycine or its derivatives, hexamethylpropyleneamineoxime or its derivatives, ethylenebis[bis(2-ethoxyethyl)phosphine] (tetrofosmin) or its derivatives, 2,3-dimercaptosuccinic acid or its derivatives, ethylenecysteine dimer derivatives methoxyisobutylisonitrile derivatives, polyamine derivatives, pyridoxylydeneaminate derivatives, methylene diphosphonate, hydroxymethylene diphosphonate derivatives, .beta.-methyl-.omega.-phenylpentadecanoic acid or its derivatives, N-isopropylamphetamine, hippuric acid, benzylguanidine and tropane derivatives.
13. The pharmaceutical preparation according to any one of Claims 7 to 10, wherein the single or plural second drugs is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.
CA2376159A 1999-06-21 2000-06-21 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method Expired - Fee Related CA2376159C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11/173514 1999-06-21
JP17351499 1999-06-21
PCT/JP2000/004039 WO2000078352A1 (en) 1999-06-21 2000-06-21 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method

Publications (2)

Publication Number Publication Date
CA2376159A1 true CA2376159A1 (en) 2000-12-28
CA2376159C CA2376159C (en) 2010-09-14

Family

ID=15961945

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2376159A Expired - Fee Related CA2376159C (en) 1999-06-21 2000-06-21 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method

Country Status (8)

Country Link
US (2) US7029653B1 (en)
EP (1) EP1197227B9 (en)
JP (1) JP4343473B2 (en)
AT (1) ATE372785T1 (en)
CA (1) CA2376159C (en)
DE (2) DE60036382D1 (en)
ES (1) ES2290042T3 (en)
WO (1) WO2000078352A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60036382D1 (en) * 1999-06-21 2007-10-25 Nihon Mediphysics Co Ltd METHOD FOR THE ADMINISTRATION OF MEDICAMENTS WITH BINDING SAFFINITY TO PLASMA PROTEIN AND USE OF THE COMPOSITION IN THE PROCESS
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
ATE489634T1 (en) 2002-10-31 2010-12-15 Nihon Mediphysics Co Ltd IN VITRO METHOD FOR CLINICAL DIAGNOSIS.
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
US20160251261A1 (en) * 2014-03-13 2016-09-01 Stevanato Group International A.S. Method of Handling a Liquid Drug Formation
CN117030905B (en) * 2023-10-09 2024-01-05 成都华西海圻医药科技有限公司 LC-MS/MS analysis method for rapidly quantifying butanedione concentration in blood plasma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520112A (en) * 1983-03-09 1985-05-28 The Johns Hopkins University Assay method for organic calcium antagonist drugs and a kit for such an assay
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US6022541A (en) * 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
DE19648629A1 (en) * 1996-11-12 1998-05-14 Meisegeier Bernhard Dr Immunoassays for antibodies or antigens
DE60036382D1 (en) * 1999-06-21 2007-10-25 Nihon Mediphysics Co Ltd METHOD FOR THE ADMINISTRATION OF MEDICAMENTS WITH BINDING SAFFINITY TO PLASMA PROTEIN AND USE OF THE COMPOSITION IN THE PROCESS

Also Published As

Publication number Publication date
EP1197227B1 (en) 2007-09-12
US20060140857A1 (en) 2006-06-29
ES2290042T3 (en) 2008-02-16
DE60036382T2 (en) 2008-06-12
DE60036382D1 (en) 2007-10-25
EP1197227A4 (en) 2002-12-04
DE60036382T4 (en) 2008-09-25
CA2376159C (en) 2010-09-14
WO2000078352A1 (en) 2000-12-28
EP1197227B9 (en) 2008-06-11
ATE372785T1 (en) 2007-09-15
JP4343473B2 (en) 2009-10-14
US7029653B1 (en) 2006-04-18
EP1197227A1 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
Lange et al. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases
Verbruggen Radiopharmaceuticals: state of the art
CA2191951C (en) Monoamine, diamide, thiol-containing metal chelating agents
Lewis et al. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy
Dash et al. Targeted radionuclide therapy-an overview
CA2376159A1 (en) Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
CA2224153A1 (en) Radiolabeled peptide compositions for site-specific targeting
GR3029318T3 (en) Bicyclopolyazamacrocyclophosphonic acid complexes, their preparation, conjugates and radiopharmaceuticals
Volkert et al. Technetium-99m chelates as radiopharmaceuticals
M Rey Radiometal complexes in molecular imaging and therapy
Altai et al. On the prevention of kidney uptake of radiolabeled DARPins
Lyczko et al. 211At labeled substance P (5–11) as potential radiopharmaceutical for glioma treatment
Iznaga-Escobar Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors—a review of radiolabeling characteristics, quality control and in vitro stability studies
TWI441650B (en) Oxidized avidin with high residency time in the treated tissues
Pak et al. An instant kit method for labeling antimyosin Fab′ with technetium-99m: evaluation in an experimental myocardial infarct model
WO1998027100A1 (en) Radioactive transition metal nitride hetero-complex
Mahmood et al. 10. TECHNETIUM RADIOPHARMACEUTICALS
Janota et al. Oxidation of methionine—is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?
Murud et al. Synthesis, purification, and in vitro stability of 211At-and 125I-labeled amidobisphosphonates
Pak et al. Labeling and stability of radiolabeled antibody fragments by a direct 99mTc-labeling method
Blower Rhenium-188 radiochemistry: challenges and prospects
AU778834B2 (en) Fatty acid analogs for diagnosis of coronary artery disease
Ertay et al. New radiolabeled CCK-8 analogues [Tc-99m-GH-CCK-8 and Tc-99m-DTPA-CCK-8]: preparation and biodistribution studies in rats and rabbits
Vallabhajosula et al. Pathophysiology and mechanisms of radiopharmaceutical localization
Santimaria et al. Experiments on a new phosphine-peptide chelator for labelling of peptides with Tc-99m

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150622